Abstract Therapeutic monoclonal antibodies (mAb) targeting soluble inflammatory cytokines exert their pharmacological effects in rheumatoid arthritis through binding and neutralizing free cytokines in target tissue sites. Therefore suppression of free cytokines in such sites directly relates to the magnitude of therapeutic response. Although the interrelationships between mAb and cytokines have been examined in the systemic circulation, less is known about the interaction of mAb and cytokines in inflamed joints. In the present study, the interplay between the mAb, CNTO 345, and its target IL-6 in serum as well as ankle joint synovial fluid were characterized in collageninduced arthritic mice. A minimal physiologically-based pharmacokinetic model with target-mediated drug disposition (TMDD) features in serum and ankle joint synovial fluid was developed for the assessment of the TMDD dynamics of CNTO 345 and IL-6. Our model indicates that TMDD kinetics in ankle joints differ greatly from that in serum. The differences can be attributed to the limited tissue distribution of CNTO 345 in ankle joint synovial fluid, the significant rise of the IL-6 baseline in ankle joint synovial fluid in comparison with serum, and the relative time-scales of elimination rates between CNTO 345, free IL-6 and CNTO 345-IL-6 complex in serum and ankle joint synovial fluid.
Introduction
Soluble cytokines, such as TNF-a, IL-1 and IL-6, play pivotal roles in the pathogenesis of a variety of inflammatory diseases including rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) [1, 2] . Development of monoclonal antibodies (mAb) that target and inhibit these cytokines has gained remarkable therapeutic success [3] . Soluble cytokines serve as mediators during the initiation and propagation of inflammatory responses. They are systemically and locally secreted by tissue cells, macrophages and mast cells. Through autocrine and paracrine mechanisms, they promote inflammatory responses in target tissues [4] . Therapeutic monoclonal antibodies exert their pharmacological effects by specifically binding to the soluble cytokines in the target tissue sites, neutralizing them, and blocking their pro-inflammatory activity.
The binding process and subsequent disposition of mAbs and their targets have been well characterized with target-mediated drug disposition (TMDD) kinetics [5] [6] [7] . In a previous study, the binding and disposition kinetics of siltuximab and IL-6 in plasma was characterized with a pharmacokinetic (PK)/target engagement (TE) model via simultaneous fitting of total siltuximab, and free and total IL-6 concentration profiles in cynomolgus monkeys [8] . However, the interplay of mAb and its target is likely to be different in various tissue sites. One of the reasons is that mAb have limited tissue distribution. Thus the exposure of mAb in tissue interstitial spaces is much less than that in plasma. Also, the baseline concentrations of many soluble cytokines are elevated in the inflamed tissues [9, 10] . Moreover, the elimination of cytokines in plasma is believed via catabolism, while in tissues, lymphatic drainage might be their dominant egress pathway.
As the suppression of free cytokines in target tissues directly correlates with the efficacy of therapeutic mAbs, it is important to examine the tissue distribution of mAbs as well as their interactions with target cytokines therein to make reliable assessment of pharmacological responses. However, little is known about the binding and disposition kinetics of mAbs and soluble cytokines in tissue sites.
The second-generation minimal physiologically-based pharmacokinetic (mPBPK) model introduced by Cao and Jusko [11] provides a modeling approach to assess tissue distribution of mAb. The mPBPK model inherits the essential components of mAb pharmacokinetics from full PBPK models. The model includes plasma, lymph, and two lumped tissue spaces (tight or leaky) based on their vascular endothelial structure (continuous or fenestrated) connected in an anatomical manner. Para-vascular convection and lymph drainage are assumed to be the dominant mechanisms for mAbs movement from plasma to tissue sites and return to plasma. Tissue interstitial space is assumed the major extravascular distribution space. Moreover, the mPBPK model has the flexibility to incorporate additional tissue compartments when measurements are available for tissues of interest. More importantly, the mPBPK model has the feasibility to implement TMDD kinetics in both plasma and tissue compartments [12] . Such models can serve to examine the interrelationship between mAb and its target entities either in the systemic circulation or in tissues of interest.
The collagen-induced arthritis (CIA) mouse model is the most commonly studied autoimmune model of rheumatoid arthritis. Compared to healthy mice, CIA mice resemble human rheumatoid arthritis with inflamed ankle joint and paw edema. A mechanistic PK/PD study was recently conducted to assess the binding and disposition kinetics of a mAb and its soluble target IL-6 in the systemic circulation and, more importantly, in target tissue sites in CIA mice [13] . Here, an mPBPK modeling approach incorporating TMDD was applied to quantitatively assess the kinetics and interrelationship between CNTO 345 and IL-6 in both serum and joint lavage fluid.
Materials and methods

Test articles
A rat anti-mouse IL-6 mAb, CNTO 345, was produced at Janssen R&D, LLC (Spring House, PA, USA) and used in the study.
Animal study design and sample collection
The CIA mice were randomly assigned to 3 groups (n = 42 9 3) and given single intravenous (IV) bolus injections of CNTO 345 at doses of 0.3, 3, and 30 mg/kg. Another group of healthy controls (n = 42) was given an IV bolus dose of 30 mg/kg CNTO 345. Serial blood samples were collected at various time points via retro-orbital bleeding (at 8 h, and 2, 5 and 10 days) and terminally via cardiac puncture (at 2 h, 1, 3, 7, 14 and 21 days). Ankle joint lavage samples were collected at the terminal time points with flush using 100 lL of PBS containing 0.1 % BSA for each joint. The fluid samples were then collected and pooled from both hind ankles. To determine IL-6 baseline concentrations, blood and joint lavage samples were obtained from another group of CIA and healthy mice (n = 7 9 2) without mAb dosing.
Bioanalytical methods
The concentrations of CNTO 345 in serum and joint lavage were quantified by by a fluoresence-based immunoassay on the Gyrolab TM xP platform (Gyros AB, Uppsala, Sweden). The lower limits of quantification (LLOQ) for serum and joint lavage CNTO 345 concentrations were 20 and 2 ng/ mL. The total and free IL-6 in serum and joint lavage fluid were determined using an electrochemiluminescence-based immunoassay (ECLIA) using the Meso Scale Discovery (MSD Ò ) platform (Meso Scale Discovery, Rockville, MD, USA) with LLOQs of 27.4 and 8.23 pg/mL for total and free IL-6 concentrations in serum and 27.4 and 6.17 pg/mL for total and free IL-6 concentrations in joint lavage samples. The details of the bioanalytical assays were described in a separate publication [13] .
Pharmacokinetics of CNTO 345 and its interplay with IL-6 in serum and joint
The mPBPK modeling approach with TMDD [11] was applied to characterize the pharmacokinetics of CNTO 345 and its interplay with IL-6 in serum and joint fluid. A stepwise modeling strategy was adopted for model development as illustrated in Fig. 1 . The serum concentrations of CNTO 345 were used to describe the pharmacokinetics of mAb with the second-generation mPBPK model in the first step (Fig. 1a) . Then more model complexities were incorporated stepwise by including additional datasets (Fig. 1b-d ). An 'ankle joint synovial fluid' tissue compartment was incorporated to characterize the distribution of CNTO 345 to the ankle joint in Step III (Fig. 1c) . The interactions between CNTO 345 and IL-6 in serum and ankle joint were examined with the TMDD feature [12] in serum and ankle joint synovial fluid in Step II and Step IV (Fig. 1b, d ). Parameters estimated in the prior step were fixed for model fitting in each subsequent step.
Step I: Serum pharmacokinetics of CNTO 345
Serum concentration profiles of CNTO 345 in healthy control (30 mg/kg) and CIA mice (0.3, 3 and 30 mg/kg) were examined. The model includes serum, lymph, and two lumped tissue compartments (leaky and tight based on vascular endothelium structures) connected in an anatomical manner (Fig. 1a) . CNTO 345 was assumed to be eliminated from serum. The model was described by:
where C s is the total concentration of CNTO 345 in serum, C tight and C leaky are concentrations of CNTO 345 in interstitial fluid (ISF) in two types of lumped tissues categorized by continuous and fenestrated vascular endothelium, and 
For healthy control mice:
where CL CIA and CL ctrl represent the linear clearances in CIA and healthy control animals, and the V max and K m terms account for the nonlinear elimination.
Step II: TMDD of CNTO 345 with IL-6 in serum
The interplay of CNTO 345 and IL-6 in serum was characterized using TMDD kinetics (Fig. 1b) . Serum concentration-time profiles of total CNTO 345 as well as free and total IL-6 in CIA mice (0.3, 3 and 30 mg/kg) were assessed. Due to significant suppression of the free IL-6 at the highest dose (30 mg/kg), the free IL-6 concentrations were all below the LLOQ (BLQ) during the early time points. Therefore only concentrations of free IL-6 after day 14 in CIA mice at 30 mg/kg were included in model fitting. The IL-6 concentrations in control mice were BLQ and free IL-6 concentrations remained BLQ following CNTO 345 administration for most time points, therefore data from healthy mice were excluded. The model was described as follows:
where C free is the free CNTO 345 concentration in serum, the R total and AR are the total IL-6 and the CNTO 345-IL-6 complex concentrations in serum, k syn and k deg are the rate constants for IL-6 biosynthesis and degradation in serum, and k int refers to the elimination rate constant of CNTO 345-IL-6 complex in serum.
The formed CNTO 345-IL-6 complex is also supposed to circulate through plasma and tissues. However, CNTO 345-IL-6 complex accounted minimally to total CNTO 345 concentrations across the entire sampling time and all dose groups (less than 5 % as indicated by the ratio of free and total CNTO 345 concentration, see supplemental materials). In our model, tissue distribution of CNTO 345-IL-6 complex was not included for simplification purpose.
Assuming quasi-equilibrium condition, C free can be described as [7] :
The K ss is the steady-state constant defined as:
where the k on and k off refer to the CNTO 345-IL-6 association and dissociation rate constants. AR can be described as:
Step III: Distribution of CNTO 345 to the ankle joint
The distribution kinetics of CNTO 345 in ankle joint was characterized by incorporating an 'ankle joint synovial fluid' compartment ( Fig. 1c) . Together with Eqs. 6-13, the model addition was:
where C sf is the concentration of CNTO 345 in ankle joint synovial fluid, L joint and V joint are lymphatic flow and volume of synovial fluid in a single ankle joint. The quantity of CNTO 345 in joint synovial fluid is minimal. Therefore the impact of CNTO 345 outflow from ankle joint on serum CNTO 345 is negligible and was not included. The volume of synovial fluid in the mouse ankle joint could not be found in the literature. The volume of synovial fluid (V joint ) of a single ankle joint was estimated in healthy mice based on the relationship between V joint , articular cartilage surface area (AC), and synovial membrane surface area (SM) as reported previously [14] :
The AC and SM values in mouse ankle joints were obtained from the literature [15] . In CIA mice, it is commonly assumed that inflammation produces leakier synovial membranes and retention of synovial fluid. However, there is no quantitative correlation between synovial fluid volume in healthy and inflamed joints. We assumed that the synovial fluid volume is increased by twofold in the inflamed joints (see ''Discussion'' section).
Concentration profiles of CNTO 345 in joint lavage in healthy controls (30 mg/kg) and CIA mice (3 and 30 mg/ kg) were applied for model fitting. As anticipated, most of the CNTO 345 concentrations in joint lavage in 0.3 mg/kg dose group in CIA mice were BLQ, and they were not used for modeling fitting. The joint lavage sampling procedure caused dilution of CNTO 345 concentration. Therefore the concentration of CNTO 345 in joint lavage (C jl ) was:
where the dilution factor is: dil ¼ V buffer =V joint The V buffer is the total volume of buffer (100 lL for one single ankle joint) used for rinsing the ankle joint capsule.
Step IV: TMDD of CNTO 345 with IL-6 in ankle joint
The interplay of CNTO 345 and IL-6 in ankle joints was characterized with a TMDD feature (Fig. 1d) . Joint lavage concentration profiles of total CNTO 345 at 3 and 30 mg/ kg doses, free IL-6 at 0.3 and 3 mg/kg doses, and total IL-6 at 0.3, 3 and 30 mg/kg doses in CIA mice were used for model fitting. Together with Eqs. 6-14, the model was described as:
where C free_j is the free CNTO 345 concentration in the joint synovial fluid, R total_j and AR j are the total IL-6 and the CNTO 345-IL-6 complex concentrations in the joint synovial fluid, k syn_j is the rate constant for IL-6 biosynthesis, k deg_j is the degradation rate constant of IL-6 in the ankle joint, and k int_j refers to the elimination rate constant of CNTO 345-IL-6 complex in joint synovial fluid. The remaining symbols are the same as previously described. Assuming quasi-equilibrium condition, the free CNTO 345 concentration in ankle joint synovial fluid was described as:
where K ss_j is the steady-state constant in ankle joint defined as:
The k on and k off refer to the association and dissociation rate constants of CNTO 345 and IL-6. The CNTO 345-IL-6 complex concentration in joint synovial fluid (AR j ) was described as:
Owing to dilution of synovial fluid during joint lavage process, the binding equilibrium between CNTO 345 and IL-6 will shift. A portion (a) of mAb-IL-6 complex will dissociate to reach a new equilibrium condition. This was described as:
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Solving Eq. 22, where K D is the in vitro equilibrium dissociation constant:
Joint lavage sampling is considered an in vitro process. Therefore K D instead of K ss was applied.
The free concentration of IL-6 in joint lavage samples (R free_jl ) is:
The total concentration of IL-6 in joint lavage samples (R total_jl ) is:
Model fitting and analysis
Model fittings were performed with NONMEM version 7.2 (ICON Development Solutions, Ellicott City, MD, USA) using naïve pooling of data. Since data were from serial destruction and being pooled together, between-subject variability (IIV) was not considered and the omega matrix was fixed to zero. The first-order (FO) method was used. The variance model used is
where V i is the variance of the ith observation, r a and r p are additive and proportional variance model parameters, Y i is the ith model prediction. Measurements BLQ were treated as missing values. Model performance was evaluated by goodness-of-fit plots and objective function values (OFV). A nonparametric bootstrap was conducted with 100 replicates in order to obtain uncertainty in the parameter estimates. The R version 2.15.3 (Free Software Foundation, Boston, MA, USA) was used for producing graphs.
Results
CNTO 345, free and total IL-6 concentrations in serum and joint lavage samples
The
Step I to Step IV model fitting results, as well as the observed total CNTO 345, and free and total IL-6 concentration versus time profiles in serum and joint lavage samples are shown in Figs. 2, 3, 4 and 5. CNTO 345 exhibited higher clearance in CIA mice compared to healthy controls (Fig. 2) . Non-compartmental analysis showed that CNTO 345 exhibited nonlinear pharmacokinetics in CIA mice and the clearance also decreased *twofold when the dose of CNTO 345 increased from 0.3 to 30 mg/kg. The ratios of CNTO 345 concentrations in joint lavage and serum ranged between 0.01 and 1 % (compare Figs. 2, 4) . Since the preparation process of joint lavage involved considerable dilution of synovial fluid, the actual CNTO 345 concentration in synovial fluid would be much higher.
The baseline IL-6 concentrations in serum were at least tenfold elevated in CIA mice compared with healthy controls (IL-6 was not detectable in healthy controls). Interestingly, the baseline concentrations of IL-6 in serum and joint lavage samples were in a similar range (compare Figs. 3, 5 ), indicating that IL-6 baseline concentrations in inflamed joints are much higher than that in serum, considering the significant dilution during joint lavage preparation.
Following the dosing of CNTO 345 at 0.3, 3 and 30 mg/ kg, the duration and extent of the free IL-6 suppression were dose-dependent in both serum and joint lavage samples (Figs. 3, 5 ). Substantial accumulation of total IL-6 was observed in serum (Fig. 3) . In contrast, the accumulation of total IL-6 in joint lavage samples was minimal (Fig. 5) .
Pharmacokinetics of CNTO 345 and its interplay with IL-6 in serum and joints
Serum pharmacokinetics of CNTO 345 (Step I)
Model-fitted serum concentrations of CNTO 345 are overlaid with observed concentrations in healthy and CIA mice in Fig. 2 . Diagnostic plots are provided in the
supplemental materials. The parameter estimates and the relative standard errors (RSE) are listed in Table 1 . Uncertainty in parameter estimates was calculated by performing a nonparametric bootstrap as listed. Overall, the model was able to capture the serum concentration profiles of CNTO 345 reasonably well. The linear clearance of CNTO 345 in CIA mice is two-to threefold higher compared to healthy controls (0.453 vs. 0.187 mL/day) and the MM elimination accounts for *50 % of the total clearance in CIA mice (V max /K m is 0.657 mL/day). Importantly, the MM elimination mechanism of CNTO 345 in CIA mice does not appear to be related to the TMDD of CNTO 345 with IL-6, since the total IL-6 concentration remain orders of magnitude lower than that of CNTO 345. The vascular reflection coefficient of tight tissue (r 1 ) was fixed to 0.98 to obtain precise parameter estimates [11] . The estimated vascular reflection coefficient of leaky tissue (r 2 ) values in healthy and CIA mice are 0.449 and 0.334, suggesting enhanced tissue distribution in CIA mice.
TMDD of CNTO 345 with IL-6 in serum (
Step II)
The TMDD feature was incorporated into the serum compartment to simultaneously fit the serum concentration-time profiles of total CNTO 345, and free and total IL-6. Model parameters estimated in step I were fixed in step II. The model fitted curves were then overlaid with the measured concentration-time profiles in Fig. 3 . The model was able to describe the concentration time courses of CNTO 345, and free and total IL-6 in serum reasonably well. The estimated elimination rate constant (k int ) for CNTO 345-IL-6 complex is 6.91 day -1 , which translates to a clearance of 5.87 mL/day. The serum clearance of the CNTO 345-IL-6 complex is *fivefold greater than that of the free CNTO 345 (CL CIA ? V max /K m is 1.11 mL/day). The estimated baseline concentration of IL-6 is 0.0029 pmol/mL (74 pg/mL) in serum of CIA mice. The degradation rate constant (k deg ) of IL-6 in serum is 835 day -1 , indicating rapid turnover dynamics (half-life of IL-6 is approximate 1.2 min). The estimated k deg of IL-6 in mice serum is consistent with previous studies with cynomolgus monkeys (k deg is 232 day -1 ) and rats (calculated k deg is 333 day -1 based on half-life of 3 min) [8, 16] . The elimination rate constants of the IL-6 and CNTO 345-IL-6 complex differ greater than 100-fold (835 vs. 6.91 day -1 ). The much slower elimination rate of the CNTO 345-IL-6 complex leads to the build-up of complex concentrations and accumulation of total IL-6 following CNTO 345 treatment. The estimated K ss is 0.0703 nM, which is in accordance with the in vitro K D value (0.015 nM). 
Distribution of CNTO 345 to the ankle joint
Ankle joint synovial fluid concentrations of CNTO 345 were used to characterize the tissue distribution of CNTO 345 to ankle joints in healthy and CIA mice. Parameters estimated in step I and II were fixed in step III. The uptake and clearance of CNTO 345 were governed by convection and lymph drainage in the ankle joint. The model-fitted concentration curves were overlaid with measured CNTO 345 concentration profiles in joint lavage at all doses in Fig. 4 . Overall, the observed profiles were well-captured with the model. For the lowest dose group (0.3 mg/kg), although most of the concentration measurements fall BLQ and were not included in model fitting, model simulation was able to describe the trend of the concentration profile. The estimated joint vascular reflection coefficients in healthy and CIA mice are 0.868 and 0.734 (r j_ctrl and r j_CIA ). This suggests that permeability of CNTO 345 is increased in inflamed ankle joints compared with normal ankle joints. The estimated lymph flow rates in normal and inflamed ankle joints are 0.0024 and 0.0128 mL/day (L joint_ctrl and L joint_CIA ), which are in agreement with the calculated lymph flow rate from the literature (0.004 and 0.008 mL/day derived from albumin half-life (3.9 h) in joints of rabbits using an allometric exponent factor of 0.25) [17] . The lymph flow rate in joint was calculated from the half-life of albumin in joint synovial fluid, using a method introduced by Levick [18] . Briefly, following an intra-articular bolus dose of radio-labeled albumin, the loss of albumin (m alb ) in synovial fluid follows mono-exponential decay as:
The albumin half-life in mouse (t half_mouse ) is then scaled from rabbit (t half_rabbit ): Because the dominant elimination pathway of macromolecules in the joint capsule is lymphatic drainage (L joint ), the L joint is:
TMDD of CNTO 345 with IL-6 in ankle joints (step IV)
Finally, the TMDD feature was incorporated into the tissue compartment of the ankle joint synovial fluid to simultaneously fit the concentration profiles of total CNTO 345, and free and total IL-6 in joint lavage samples from CIA mice. Parameters estimated from Step I to III were fixed in step IV. The model-fitted curves were overlaid with the measured concentration-time profiles in Fig. 5 . In general, the observed profiles of all the components were well characterized with the model. The elimination rate constant of CNTO 345-IL-6 complex in joint synovial fluid (k int_j ) is 21.6 day . This translates to a clearance of CNTO 345-IL-6 complex of 0.0129 mL/day, which is extremely close to the estimated ankle joint lymph flow (0.0128 mL/day), suggesting that elimination of CNTO 345-IL-6 complex is likely through lymph drainage. The estimated baseline concentration of IL-6 is 0.251 pmol/mL (6.52 9 10 3 pg/mL) at the joint in CIA mice, which is 100-fold higher compared to serum (0.0029 pmol/mL). The fold difference of IL-6 baseline in serum and synovial fluid in CIA mice is in agreement with the observations of baseline IL-6 in serum (79.9 ± 60.5 pg/mL) and joint synovial fluid (15134 ± 17263 pg/mL) in RA patients [10] . The degradation rate constant of IL-6 in joint (k deg_j ) is 52.6 day
, which translates to a clearance in ankle joint of 0.0317 mL/day. In contrast to the serum situation, the elimination rate constants of free IL-6 and CNTO 345-IL-6 complex in the joint are similar (52.6 vs. 21.6 day -1 ). As a result, minimal accumulation of total IL-6 in joint lavage fluid samples was observed. The estimated K ss_j in joints is 0.425 nM, which is greater than K ss in serum (0.0703 nM). Assuming the k off /k on value in both serum and joints equals the in vitro K D (0.015 nM), the increase in K ss_j can almost be attributed entirely to the higher elimination rate constant of CNTO 345-IL-6 complex in joint (52.6 vs. 6.91 day -1 in serum).
Discussion
In summary, the developed mPBPK model with TMDD features in serum and ankle joint synovial fluid well characterized the pharmacokinetics of CNTO 345 and its interplay with soluble cytokine IL-6 in serum and ankle joints.
Modeling was formed in a step-wise manner. The overall datasets includes both CNTO 345 and IL-6 concentrations in serum, as well as in joint lavage, which convey information of CNTO 345 pharmacokinetics and target engagement with IL-6 with various degrees of variabilities. Fitting datasets sequentially will lead to estimation of CNTO 345 serum pharmacokinetics parameters first with less uncertainty. These parameters are then fixed to drive the estimation of other parameters related to CNTO 345 ankle joint distribution and target engagement, which have greater uncertainty. Also, the objective of this modeling effort was to infer knowledge about the CNTO 345 kinetics for targeting binding and disposition in serum as well as in synovial tissue. Having all parameters simultaneously estimated led to identifiability issue with some of the parameters, which are quite important to understand CNTO 345 targeting binding and disposition.
Our model indicates that the dynamics of the interaction between CNTO 345 and IL-6 in serum and ankle joints differ greatly. This likely to be attributed to: (1) limited tissue distribution of CNTO 345 in ankle joint synovial fluid; (2) higher IL-6 baseline in ankle joint synovial fluid in comparison with serum; and (3) significant differences in the relative time-scales for the elimination rates of free CNTO 345, free IL-6 and CNTO 345-IL-6 complex, which are the three players in the TMDD system, in systemic circulation and ankle joint synovial fluid.
Extravasation of mAbs in tissues is predominantly governed by convection and the efficiency of convection is dependent on the fluid flow rate and the permeability of the vasculature. Comparison of the r 2 values between CIA mice and normal control mice (0.334 vs. 0.449) confirmed that inflammation can cause increased vascular permeability and therefore enhanced mAb tissue distribution.
CNTO 345 shows enhanced tissue distribution to the ankle joint synovial fluid in CIA mice compared with healthy controls. The estimated vascular reflection coefficients (r j_ctrl and r j_CIA ) suggest twofold increase of vascular permeability in CIA mice. This corresponds well with our previous study showing that inflammation causes increased vascular permeability and enhanced tissue distribution of etanercept in arthritic paws in CIA rats [19] .
The estimate of r j for the ankle joint is highly dependent on the volume of synovial fluid and the dilution factor used for the model-fitting. Firstly, the procedure for sampling joint lavage fluid does not enable accurate estimation of dilution of synovial fluid. Secondly, the volume of ankle joint synovial fluid in mice is not directly available from literature. We have derived the ankle joint synovial fluid volume in healthy mice based on the relationship between synovial membrane surface area (SM) and synovial fluid volume [14] . To validate the relationship, knee joint SM values from various species reported in the literature were used to calculate the knee joint synovial fluid volumes and compared with the measured values from publications. As Table 2 shows, the calculated synovial fluid volumes are consistent with the measured values. In CIA mice, inflammation leads to increased vascular permeability and fluid retention in synovial tissue. The increase of synovial fluid volume has an upper limit due to space constraint within the joint capsule (cannot exceed tenfold in ankle joint). Therefore the fold-change of synovial fluid in CIA mice ankle joint should be between 1 and 10. A 'twofold' increase was assumed for modeling, and the assumption lead to L joint estimates that are physiologically relevant. The L joint estimates would differ if a different fold-change Step IV: TMDD in ankle joint Total lymphatic flow allometrically scaled from human (2.9 L/day) with exponent factor 0.74 c Synovial fluid volume of mouse ankle joint in healthy mice estimated from mouse ankle joint synovial membrane values [14, 15] d Synovial fluid volume of mouse ankle joint was assumed to increase by twofold in CIA mice compare to healthy mice was assumed, but not too significantly within the one to tenfold as specified above. Regardless, this will not change any of our major conclusions. IL-6 is highly expressed in inflamed joints and the baseline concentration of IL-6 in ankle joint synovial fluid is approximately 100-fold higher than in the systemic circulation. This is a result of both strong local production of IL-6 in the inflamed tissue, and its slower clearance from the joint than in serum. IL-6 was shown to be produced and functions locally in the joints of RA patients [20] . Upon stimulation by TNF-a and IL-1, IL-6 is produced in large amounts by synovial fibroblast cells [21] . Notably, given the small volume of ankle joint synovial fluid, the amount of IL-6 being produced in ankle joint is insignificant to the whole body.
The relative time-scale differences among the elimination rates of CNTO 345, free IL-6 and CNTO 345-IL-6 complex differs profoundly in ankle joint synovial fluid in comparison with serum. In serum, the clearances of CNTO 345 and CNTO 345-IL-6 complex are approximately 100-fold slower compared to free IL-6. This would lead to a significant accumulation of total IL-6 upon CNTO 345 treatment. In contrast, the clearances of CNTO 345 and CNTO 345-IL-6 are on the same time-scale with free IL-6 in joints, and thus minimal accumulation of total IL-6 was observed. The accumulation of total IL-6 would limit the duration of free IL-6 suppression as it dissociates. Moreover, the turnover rate of IL-6 is *tenfold faster in serum than in joint synovial fluid, which indicates that the production rate difference between serum and joint ([tenfold) is less than that in their baselines ([100-fold). All these factors contribute to the relatively long duration of free IL-6 suppression despite the lower mAbs concentrations in the joint.
Our model made no assumptions about the elimination mechanisms of free IL-6 and CNTO 345-IL-6 complex in serum and ankle joint synovial fluid and simple first-order elimination rate constants were assigned. Interestingly, the model parameter estimates allow us to speculate the likely elimination pathways for free IL-6 and CNTO 345-IL-6 complex from serum and joints. In serum, the estimated clearance of CNTO 345-IL-6 complex in serum is much closer to the clearance of CNTO 345. Elimination of CNTO 345 in serum is believed via catabolism. The rapid turnover rate of free IL-6 is consistent with the rapid elimination of small soluble cytokines by liver and kidney. In ankle joint synovial fluid, the removal of free CNTO 345 was assumed to be via lymph flow. Interestingly, the estimated clearance of the CNTO 345-IL-6 complex is extremely close to the lymph flow, which indicates that lymph drainage also account for the elimination of CNTO 345-IL-6 complex. Free IL-6 clearance from the joint is *2.5-fold higher than lymph flow, indicating that both lymph drainage and local degradation contributed to its elimination. But the local degradation of free IL-6 is significantly lower comparing to what happens systemically.
With the joint lavage sampling procedure, the ankle joint synovial fluid samples are highly diluted. Dilution will cause dissociation of the CNTO 345-IL-6 complex and the binding equilibrium would be shifted [22] . Therefore, in our model development, the dissociation of the CNTO 345-IL-6 complex due to dilution was quantitatively accounted for. Since many analytical approaches require dilution, careful interpretation of such data is needed. Misleading characterization of the TMDD dynamics would occur if such dilution effect on the ligand binding equilibrium was not considered.
The developed mPBPK model with TMDD provided decent performance in describing the concentration profiles of CNTO 345, and free and total IL-6 in serum and ankle joint lavage. However, there are limitations with the model assumptions. The model assumes that the production of IL-6 for the full time course of CIA disease progression is the same. However, since the expression of IL-6 is correlated with disease severity [13] , this assumption may not hold true all the time, especially over long-term treatment. Also, the model assumes the same synovial fluid volume for inflamed ankle joints for all CIA mice, which can only be an approximation.
In conclusion, the interrelationships of CNTO 345 and IL-6 in serum and joints differ greatly. The difference can be attributed to limited tissue distribution of CNTO 345, significant rise of the baseline IL-6 in joint synovial fluid, and the time-scales among the eliminations rates of CNTO [31] 345, IL-6, and the complex. Simple extrapolation of free cytokine suppression in tissues assuming similar dynamics of TMDD of mAb and cytokine in serum and tissues would lead to errant conclusions. Our modeling efforts to decipher the interplay of CNTO 345 and IL-6 in the systemic circulation and inflamed joints shed some light on possible mechanisms of TMDD of mAb and soluble cytokines in joint synovial fluid, which helps in better projection of free cytokine suppression in inflamed joints. The quantitative interrelationships between mAb and soluble cytokines obtained in mice, incorporating additional information about the expression and dynamics of soluble cytokines in RA patients, could possibly allow translation into humans and better predictions of therapeutic responses.
